Incretin pharmacology spent decades focused on a single receptor before researchers began asking what a second one might add.
An incretin research question
By the early 2010s, GLP-1 receptor agonists were an established and productive area of metabolic research, with molecules like semaglutide demonstrating that a modified peptide could reliably activate the GLP-1 receptor with an extended duration of action. That success raised an obvious follow-up question in incretin biology: GLP-1 is not the only incretin hormone. GIP (glucose-dependent insulinotropic polypeptide) is released alongside GLP-1 after nutrient intake and signals through its own distinct receptor, yet most drug-discovery effort up to that point had concentrated on GLP-1 alone, partly because GIP's role in metabolic regulation was less well characterized and more debated in the literature.
From single to dual agonism
Tirzepatide was developed as a single synthetic peptide engineered to activate both the GIP and GLP-1 receptors, rather than as a mixture of two separate agonists. Its backbone borrows structurally from native GIP, modified at key positions so that it can also engage the GLP-1 receptor, and it carries a fatty-diacid side chain — a design approach already validated in other long-acting peptide programs — to extend its circulating half-life. In the literature, tirzepatide was originally referred to by its development code before it acquired the name used in research publications today, a naming pattern typical of compounds that move from early discovery work into wider study. That unimolecular dual-agonist design was a significant departure from co-administering two separate compounds, since it meant a single pharmacokinetic profile could be studied for both receptor activities at once, simplifying comparative research considerably.
A benchmark molecule
As tirzepatide moved through preclinical and later research programs, it became a reference point that subsequent dual- and multi-receptor agonists were compared against. Once triple-receptor molecules such as retatrutide — which adds glucagon-receptor activity on top of the GIP/GLP-1 pair — entered study, tirzepatide's two-receptor design served as the intermediate step in that lineage, situated between single-agonist compounds and triple agonists. The receptor biology underlying all of these designs is summarized in GLP-1, GIP & glucagon: the incretin receptors explained. Today, tirzepatide is most often discussed in the literature not as a standalone finding but as the middle rung on that dual-to-triple-agonist ladder, which is why so much contemporary research design treats it as a comparator rather than an endpoint in itself, a role that has only become more prominent as newer multi-receptor candidates have entered the same research literature.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.
See a third-party–tested compound: BPC-157 (batch COA available) →